1-(6-溴吡啶-3-基)环丙烷甲腈 | 827628-16-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-(6-溴吡啶-3-基)环丙烷甲腈
• 英文名称: 1-(6-bromo-3-pyridyl)cyclopropanecarbonitrile
• 英文别名: 1-(6-Bromopyridin-3-YL)cyclopropanecarbonitrile；1-(6-bromopyridin-3-yl)cyclopropane-1-carbonitrile
• CAS: 827628-16-0
• 化学式: C₉H₇BrN₂
• 分子量: 223.072
• InChiKey: GPEPQUOJSLPUNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  1-(6-溴吡啶-3-基)环丙烷甲腈 、 tert-butyl N-[(1S)-4-(6-bromo-8-fluoro-1-oxo-2-isoquinolyl)-1-methyl-butyl]carbamate 在 四羟基二硼 、 XPhos Pd G2 、 potassium acetate 、 2-二环己基磷-2,4,6-三异丙基联苯 、 potassium carbonate 作用下， 以 乙醇 、 水 为溶剂， 生成 tert-butyl N-[(1S)-4-[6-[5-(1-cyanocyclopropyl)-2-pyridyl]-8-fluoro-1-oxo-2-isoquinolyl]-1-methylbutyl]carbamate
  参考文献：
  名称：

  WO2023/147418

  摘要：

  公开号：

文献信息

• Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo
  申请人：Fukuda Yasumichi

  公开号：US20070185132A1

  公开（公告）日：2007-08-09

  This invention relates to new oxazolidinones having a cyclopropyl moiety, which are effective against aerobic and anerobic pathogens such as multi-resistant staphylococci, streptococci and enterococci, Bacteroides spp., Clostridia spp. species, as well as acid-fast organisms such as Mycobacterium tuberculosis and other mycobacterial species. The compounds are represented by structural formula I: its enantiomer, diastereomer, or pharmaceutically acceptable salt or ester thereof.

  本发明涉及具有环丙基基团的新型噁唑烷酮，对厌氧和厌氧病原体如多重耐药葡萄球菌、链球菌和肠球菌、Bacteroides spp.、Clostridia spp.物种以及抗酸菌如结核分枝杆菌和其他分枝杆菌物种有效。该化合物由结构式I表示：其对映异构体、顺异构体或其药学上可接受的盐或酯。
• SUBSTITUTED PROLINES / PIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Eolas Therapeutics, Inc.

  公开号：US20140364432A1

  公开（公告）日：2014-12-11

  The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as OX 1 or OX 2 , or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease.

  本发明涉及化合物，可以调节促觉醒肽受体（如OX1或OX2，或两者）的生物活性；涉及含有本发明化合物的药物组合物；涉及在患者中调节促觉醒肽受体是医学上指示的异常情况的治疗方法；以及涉及本发明化合物的制备方法。例如，本发明的促觉醒肽受体调节化合物可用于治疗进食障碍、肥胖症、酗酒或与酒精相关的疾病、药物滥用或成瘾（包括可卡因、鸦片类、苯丙胺或尼古丁成瘾）、睡眠障碍、精神或神经障碍中的认知功能障碍、抑郁症、焦虑症、惊恐障碍、精神分裂症、阿尔茨海默病、帕金森病、亨廷顿舞蹈病、头痛、偏头痛、疼痛、胃肠疾病、癫痫、炎症、免疫相关疾病、内分泌相关疾病、癌症、高血压、行为障碍、情绪障碍、躁郁症、痴呆症、性障碍、心理性性障碍或肾脏疾病的治疗。
• CYCLOPROPYL GROUP SUBSTITUTED OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF
  申请人：Merck & Co., Inc.

  公开号：EP1654259A1

  公开（公告）日：2006-05-10
• TRPV3 MODULATORS
  申请人：AbbVie Inc.

  公开号：US20180243298A1

  公开（公告）日：2018-08-30

  A compound of Formula (I) having efficacy for the treatment or prevention of conditions and disorders related to TRPV3 activity, e.g. pain, atopic dermatitis, eczema, itch or psoriasis, is disclosed. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
• US9440982B2
  申请人：——

  公开号：US9440982B2

  公开（公告）日：2016-09-13